<?xml version='1.0' encoding='utf-8'?>
<document id="27872071"><sentence text="Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study." /><sentence text="Doravirine is a novel, highly potent, nonnucleoside reverse transcriptase inhibitor that is administered once daily and that is in development for the treatment of HIV-1 infection"><entity charOffset="0-10" id="DDI-PubMed.27872071.s2.e0" text="Doravirine" /></sentence><sentence text=" In vitro and clinical data suggest that doravirine is unlikely to cause significant drug-drug interactions via major drug-metabolizing enzymes or transporters"><entity charOffset="41-51" id="DDI-PubMed.27872071.s3.e0" text="doravirine" /></sentence><sentence text=" As a common HIV-1 infection comorbidity, hypercholesterolemia is often treated with statins, including the commonly prescribed atorvastatin"><entity charOffset="128-140" id="DDI-PubMed.27872071.s4.e0" text="atorvastatin" /></sentence><sentence text=" Atorvastatin is subject to drug-drug interactions with cytochrome P450 3A4 (CYP3A4) inhibitors"><entity charOffset="1-13" id="DDI-PubMed.27872071.s5.e0" text="Atorvastatin" /></sentence><sentence text=" Increased exposure due to CYP3A4 inhibition may lead to serious adverse events (AEs), including rhabdomyolysis" /><sentence text=" Furthermore, atorvastatin is a substrate for breast cancer resistance protein (BCRP), of which doravirine may be a weak inhibitor; this may increase atorvastatin exposure"><entity charOffset="14-26" id="DDI-PubMed.27872071.s7.e0" text="atorvastatin" /><entity charOffset="96-106" id="DDI-PubMed.27872071.s7.e1" text="doravirine" /><entity charOffset="150-162" id="DDI-PubMed.27872071.s7.e2" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.27872071.s7.e0" e2="DDI-PubMed.27872071.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27872071.s7.e0" e2="DDI-PubMed.27872071.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27872071.s7.e0" e2="DDI-PubMed.27872071.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27872071.s7.e1" e2="DDI-PubMed.27872071.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27872071.s7.e1" e2="DDI-PubMed.27872071.s7.e2" /></sentence><sentence text=" The potential of doravirine to affect atorvastatin pharmacokinetics was investigated in a two-period, fixed-sequence study in healthy individuals"><entity charOffset="18-28" id="DDI-PubMed.27872071.s8.e0" text="doravirine" /><entity charOffset="39-51" id="DDI-PubMed.27872071.s8.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.27872071.s8.e0" e2="DDI-PubMed.27872071.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27872071.s8.e0" e2="DDI-PubMed.27872071.s8.e1" /></sentence><sentence text=" In period 1, a single dose of atorvastatin at 20 mg was administered followed by a 72-h washout"><entity charOffset="31-43" id="DDI-PubMed.27872071.s9.e0" text="atorvastatin" /></sentence><sentence text=" In period 2, doravirine at 100 mg was administered once daily for 8 days, with a single dose of atorvastatin at 20 mg concomitantly being administered on day 5"><entity charOffset="97-109" id="DDI-PubMed.27872071.s10.e0" text="atorvastatin" /></sentence><sentence text=" Sixteen subjects were enrolled, and 14 completed the trial; 2 discontinued due to AEs unrelated to the treatment" /><sentence text=" The atorvastatin area under the curve from time zero to infinity was similar with and without doravirine (geometric mean ratio [GMR] for doravirine-atorvastatin/atorvastatin, 0"><entity charOffset="5-17" id="DDI-PubMed.27872071.s12.e0" text="atorvastatin" /><entity charOffset="95-105" id="DDI-PubMed.27872071.s12.e1" text="doravirine" /><entity charOffset="162-174" id="DDI-PubMed.27872071.s12.e2" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.27872071.s12.e0" e2="DDI-PubMed.27872071.s12.e0" /><pair ddi="false" e1="DDI-PubMed.27872071.s12.e0" e2="DDI-PubMed.27872071.s12.e1" /><pair ddi="false" e1="DDI-PubMed.27872071.s12.e0" e2="DDI-PubMed.27872071.s12.e2" /><pair ddi="false" e1="DDI-PubMed.27872071.s12.e1" e2="DDI-PubMed.27872071.s12.e1" /><pair ddi="false" e1="DDI-PubMed.27872071.s12.e1" e2="DDI-PubMed.27872071.s12.e2" /></sentence><sentence text="98; 90% confidence interval [CI], 0" /><sentence text="90 to 1" /><sentence text="06), while the maximum concentration decreased by 33% (GMR for doravirine-atorvastatin/atorvastatin, 0"><entity charOffset="87-99" id="DDI-PubMed.27872071.s15.e0" text="atorvastatin" /></sentence><sentence text="67; 90% CI, 0" /><sentence text="52 to 0" /><sentence text="85)" /><sentence text=" These changes were deemed not to be clinically meaningful" /><sentence text=" Both of the study drugs were generally well tolerated" /><sentence text=" Doravirine had no clinically relevant effect on atorvastatin pharmacokinetics in healthy subjects, providing support for the coadministration of doravirine and atorvastatin"><entity charOffset="1-11" id="DDI-PubMed.27872071.s21.e0" text="Doravirine" /><entity charOffset="49-61" id="DDI-PubMed.27872071.s21.e1" text="atorvastatin" /><entity charOffset="146-156" id="DDI-PubMed.27872071.s21.e2" text="doravirine" /><entity charOffset="161-173" id="DDI-PubMed.27872071.s21.e3" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.27872071.s21.e0" e2="DDI-PubMed.27872071.s21.e0" /><pair ddi="false" e1="DDI-PubMed.27872071.s21.e0" e2="DDI-PubMed.27872071.s21.e1" /><pair ddi="false" e1="DDI-PubMed.27872071.s21.e0" e2="DDI-PubMed.27872071.s21.e2" /><pair ddi="false" e1="DDI-PubMed.27872071.s21.e0" e2="DDI-PubMed.27872071.s21.e3" /><pair ddi="false" e1="DDI-PubMed.27872071.s21.e1" e2="DDI-PubMed.27872071.s21.e1" /><pair ddi="false" e1="DDI-PubMed.27872071.s21.e1" e2="DDI-PubMed.27872071.s21.e2" /><pair ddi="false" e1="DDI-PubMed.27872071.s21.e1" e2="DDI-PubMed.27872071.s21.e3" /><pair ddi="false" e1="DDI-PubMed.27872071.s21.e2" e2="DDI-PubMed.27872071.s21.e2" /><pair ddi="false" e1="DDI-PubMed.27872071.s21.e2" e2="DDI-PubMed.27872071.s21.e3" /></sentence><sentence text="" /></document>